Pulmonary arterial hypertension (endothelin-pathway therapy): cross-border specialty drug access for international patients

Quick orientation

Pulmonary arterial hypertension affects an estimated 15 to 50 per million adults. Connective tissue disease-associated and idiopathic forms are the most common indications for endothelin-pathway therapy.

Typical age of onset. Most commonly diagnosed in adults aged 30 to 60. Women are affected more often than men.

Severity tiers. Severity is graded by WHO functional class, hemodynamics, and biomarkers. Untreated severe disease has a poor prognosis.

Why specialty drugs for Pulmonary arterial hypertension (endothelin-pathway therapy) are hard to access internationally

Endothelin receptor antagonists and combination therapies including newer activin signaling inhibitors are not always available in MENA and South Asia. Even where registered, restrictions on prescribing centers and risk-evaluation programs limit local access.

Treatments approved by the FDA

• Opsynvi (macitentan and tadalafil fixed-dose combination) — FDA approval: 2024. Mechanism: Dual endothelin receptor antagonist plus PDE-5 inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 14,000 to 18,000 per month.
• Winrevair (sotatercept) — FDA approval: 2024. Mechanism: Activin signaling inhibitor. Route: Subcutaneous injection every 3 weeks. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: UAE · Saudi Arabia · India · Egypt · Bahrain · Oman.
• Vanrafia (atrasentan) — FDA approval: 2025. Mechanism: Selective endothelin A receptor antagonist (IgAN label; PAH research). Route: Oral once daily. US WAC ballpark: Approximately USD 100,000 per year. Country pricing: UAE · Saudi Arabia · India · Kuwait · Egypt.
• Tryvio (aprocitentan) — FDA approval: 2024. Mechanism: Dual endothelin receptor antagonist (resistant hypertension label; relevant adjacent pathway). Route: Oral once daily. US WAC ballpark: Approximately USD 25,000 per year. Country pricing: Saudi Arabia · Qatar.

Cross-border pathways used for Pulmonary arterial hypertension (endothelin-pathway therapy)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm PAH subtype, WHO functional class, and current regimen.
• Right heart catheterization confirms diagnosis and informs treatment escalation.
• Endothelin antagonists carry teratogenicity warnings and require pregnancy prevention programs.
• Liver function monitoring is required for some endothelin antagonists.
• Multidisciplinary PAH center co-management is the standard of care.

Common questions

Is Winrevair available outside the US?

International registration is rolling out. We confirm by destination.

Can I combine therapies?

Most PAH regimens are combinations. Your PAH specialist guides the selection.

What is the pregnancy testing requirement?

Patients of reproductive potential must use effective contraception and document monthly negative pregnancy tests.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

PAH specialist's prescription, recent right heart catheterization report, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Pulmonary arterial hypertension (endothelin-pathway therapy), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Pulmonary arterial hypertension (endothelin-pathway therapy)

Reserved for you.